Fighting The High Cost Of Rx Drugs

AN INDUSTRY-WIDE TACTIC—At least eight of the top 10 drug makers have paid off their competition to block generics from entering the market. The FTC estimates that pay for delay deals cost consumers and taxpayers $3.5 billion every year in higher drug prices.

It's Time To End Pay For Delay

We all know prescription drugs cost too much. That’s partly because brand-name drug companies have been paying off generic drug makers to delay competition and keep prices high. This practice, called “pay for delay,” is commonplace in the pharmaceutical industry.
It's anti-competitive. It's hurting consumers. And it has to stop.

Competition is known to bring drug prices down 85-90 percent:

  • 30-day supply of the cholesterol drug Lipitor costs $194. The generic equivalent? Only $16.
  • The medication needed to prevent blood costs, Plavix, costs $205, while its generic equivalent is $13 for that same 30-day supply.
  • The antibiotic Cipro, used to treat a number of infections, costs $52; the generic costs $7.

And because drug companies can use pay for delay to maintain their strangle hold on the market long after their active-ingredient patents expire, consumers who rely on these drugs for their health are often forced to pay these higher prices for years before they see the generic.

CASE STUDY: Experts expected narcolepsy drug Provigil to go generic in 2006, but pay-for-delay deals kept the generic off the market until 2012. In the meantime, many multiple sclerosis patients had to pay over $1,200 each month for the drug, or manage without it. Bad news for consumers, but good news for the drug company. As the CEO of Cephalon, the drug company that makes Provigil, said about the deal, “We got six more years of patent protection. That’s $4 billion in sales that no one expected.”

Drug companies spend more on lobbying than any other industry. But if we build enough public support, we can stop the industry's pay-for-delay scheme and bring down drug and health care costs for consumers and taxpayers.

We're calling on Congress to put an end to pay for delay once and for all.

Issue updates

Report | U.S. PIRG | Health Care

MAINE: The Cost of Repeal

The evidence suggests that the costs of health care repeal are substantial and many of the asserted benefits of repeal do not stand up under scrutiny. But Maine's policy makers have additional options. Maine instead should adapt the law's implementation to its needs and take the steps to lower health care costs which the federal law fails to take.

> Keep Reading
Result | Health Care

Young People Now Covered

This year, the federal health care reforms that U.S. PIRG worked to win have started to pay off for young people. In the past, teens saw their premiums soar or were denied coverage when they turned 19, even if they’d been insured their whole lives. Now, they can remain on their parents’ plans until age 26. 

> Keep Reading
Report | U.S. PIRG Education Fund | Health Care

Delivering on the Promise

The recently passed federal health care reform law will make significant changes in how health insurance and health care work for consumers, businesses, and local and state governments, as well as how insurers and providers operate. But whether Americans experience improved care, lower costs and greater access depends largely on what happens next. 

> Keep Reading
Report | U.S. PIRG | Health Care


It's commonly assumed that young Americans are disengaged from the issue, that on the whole they are a healthy group who are unlikely to be affected by health problems or lack access to care. But the reality couldn't be more different. In fact, young people, including college students, are on the front lines of the health care crisis. They make up the largest age block of the uninsured, and face a uniquely challenging set of obstacles that often prevent them from getting coverage.

> Keep Reading
Report | U.S. PIRG | Health Care

The Three Trillion Dollar Question

Without health care reform, the United States is projected to spend over $40 trillion on health care in the next decade.  Experts estimate that thirty percent of that spending – up to $12 trillion dollars – will be wasted on ineffective care, pointless red tape, and counterproductive treatments that can actually harm patients.  

> Keep Reading


View AllRSS Feed


Tell your senator that patients can't afford to wait another day. We need to end "Pay for Delay" right now.

Support Us

Your donation supports U.S. PIRG’s work to stand up for consumers on the issues that matter, especially when powerful interests are blocking progress.

Consumer Alerts

Join our network and stay up to date on our campaigns, get important consumer updates and take action on critical issues.
Optional Member Code